Department of Obstetrics and Gynecology, University of Florida College of Medicine, Jacksonville, Florida; the Columbus Center for Women's Health Research, Columbus, Ohio; Mailman School of Public Health, Columbia University, New York, New York; the Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, Virginia; the Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California; ARSTAT, Flemington, New Jersey; and Agile Therapeutics, Inc, Princeton, New Jersey.
Corresponding author: Andrew M. Kaunitz, MD, Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine–Jacksonville, 653-1 West 8th Street, Jacksonville, FL 32209; e-mail: [email protected].
Portions of this manuscript were presented as a poster at both the 60th and 61st Annual Meetings of the American Congress of Obstetricians and Gynecologists, May 5–9, 2012, San Diego, California, and May 4–8, 2013, New Orleans, Louisiana.
Financial Disclosure Dr. Kaunitz is a consultant to Actavis, Bayer Healthcare, Merck, and Teva; his academic department (Department of Obstetrics & Gynecology, University of Florida College of Medicine–Jacksonville) receives financial support to conduct clinical trials from Agile Therapeutics, Inc, Bayer Healthcare, and Teva. Dr. Portman has received research grants from Agile Therapeutics, Inc, Bayer Healthcare, Teva, Warner Chilcott, Actavis, Merck, and Population Council; is a consultant to Teva and Actavis; and serves on the speakers' bureau for Teva and Warner Chilcott. Dr. Westhoff is a consultant to Bayer, Merck, Actavis, and Agile. Dr. Archer is a consultant to Abbot Laboratories, Agile Therapeutics, Inc, Bayer Healthcare, CHEMO, Endoceutics, Ferring Pharmaceuticals, HRA Pharma, Merck, Shionogi, Teva Women's Healthcare, Warner Chilcott, and Watson Pharmaceutical; has received research support from Abbott Laboratories, Bayer Healthcare, Endoceutics, Merck, Pfizer, Warner Chilcott, and Watson Pharmaceutical; and has received industry honoraria from Bayer Healthcare, Besins, and Merck. Dr. Mishell is a consultant to Agile Therapeutics, Inc. Dr. Rubin is a consultant to Agile Therapeutics, Inc. Dr. Foegh is an employee of Agile Therapeutics, Inc and has stock holdings in the company. Editorial assistance was provided by Phase Five Communications Inc, with financial support provided by Agile Therapeutics, Inc.
